HERCULES, Calif. —Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.
The Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD) is a single molecular test designed for clinical diagnostic labs that conduct COVID-19 testing. This specific respiratory panel detects the nucleocapsid gene of SARS-CoV-2, the M1 gene of flu A, and the NS2 gene of flu B in nasopharyngeal swab specimens from individuals suspected of being infected by COVID-19. Because the assay for SARS-CoV-2 is designed to target the nucleocapsid gene instead of the spike protein gene, the assay’s performance is not affected by the known coronavirus variants, as determined by in silico analysis (as of March 2021). The assay kit contains Bio-Rad’s standard and negative molecular controls as well as assay reagents. The kit is validated to run on Bio-Rad’s CFX96™ Dx Real-Time PCR System as well as real-time PCR systems from other manufacturers.
“With the upcoming flu season, a continuing COVID-19 pandemic, and many countries opening up and returning to the workplace, clinicians need a sensitive, reliable, and convenient way to detect common respiratory viruses and to differentiate cases of COVID-19 infection that do not involve flu A or flu B infection,” said Steven Blakely, Bio-Rad Global Director of Marketing, Life Science Group, Gene Expression. “We are pleased to launch the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit in Europe, providing much-needed expanded testing capacity. The kit simultaneously tests for all three viruses with high speed, sensitivity, and specificity, valuable for labs doing this important work," he said.
Please visit www.Bio-Rad.com/SC2Flu-CE-IVD to learn more about the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD).
BIO-RAD, Reliance SARS-CoV-2/FluA/FluB and CFX96 are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,700 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. Please visit bio-rad.com for further information.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contact:
Nico Tuason
510-741-1000
nico_tuason@bio-rad.com